文献速递类风湿关节炎

多层次因素预测类风湿关节炎患者的用药依从性:一项为期6个月的队列研究

Multilevel factors predict medication adherence in rheumatoid arthritis: a 6-month cohort study.
PubMed 文献 · Ann Rheum Dis · 2021-11-29

该为期6个月的前瞻性队列研究通过系统分层抽样纳入180例类风湿关节炎患者,采用两种量表评分均大于80%定义依从性,依从率为59.1%(95%CI 48.1%至71.8%)。多因素模型显示,使用二线DMARD(OR=5.22)和生物制剂(OR=3.76)、治疗一致同意(OR=4.57)、获得治疗调整信息(OR=1.42)及医生感知的患者信任(OR=1.58)与依从性独立相关。

要点

  • 类风湿关节炎患者6个月治疗依从率为59.1%(95%CI 48.1%至71.8%)。
  • 使用二线DMARD(OR=5.22)和生物制剂(OR=3.76)与更高依从性相关。
  • 心理、沟通和物流因素对依从性的影响大于社会人口学或临床因素。

核心结论

  • 类风湿关节炎的治疗依从性远未完全达标,心理、沟通和物流因素对依从性的影响大于社会人口学或临床因素。

研究设计与样本

  • 为期6个月的前瞻性队列研究,通过系统分层抽样选取类风湿关节炎患者,其中33%使用第一种改善病情抗风湿药(DMARD),33%使用二线DMARD,33%使用生物制剂。

主要发现

  • 共纳入180例患者(女性77%,平均年龄60.8岁)。
  • 依从率为59.1%(95%CI 48.1%至71.8%)。
  • 使用生物制剂的患者依从性更高且感知的药物需求更高;使用二线DMARD的患者经历的不良事件更多。
  • 最终多因素模型中解释依从性的变量为:处方治疗类型(二线DMARD OR=5.22,生物制剂 OR=3.76)、治疗一致同意(OR=4.57)、获得治疗调整信息(OR=1.42)及医生感知的患者信任(OR=1.58),这些效应独立于疾病活动度。

关键数值与推荐

  • 依从性定义为《风湿病学依从性问卷》和《用药依从性报告量表》评分均大于80%。
  • 依从率59.1%(95%CI 48.1%至71.8%)。
  • 二线DMARD的OR=5.22,生物制剂的OR=3.76,治疗一致同意的OR=4.57,获得治疗调整信息的OR=1.42,医生感知的患者信任的OR=1.58。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Non-adherence challenges efficacy and costs of healthcare. Knowledge of the underlying factors is essential to design effective intervention strategies. OBJECTIVES: To estimate the prevalence of treatment adherence in rheumatoid arthritis (RA) and to evaluate its predictors. METHODS: A 6-month prospective cohort study of patients with RA selected by systematic stratified sampling (33% on first disease-modifying rheumatic drug (DMARD), 33% on second-line DMARD and 33% on biologics). The outcome measure was treatment adherence, defined by a score greater than 80% both in the Compliance Questionnaire in Rheumatology and the Reported Adherence to Medication scale, and was estimated with 95% CIs. Predictive factors included sociodemographic, psychological, clinical, drug-related, patient-doctor relationship related and logistic. Their effect on 6-month adherence was examined by multilevel logistic models adjusted for baseline covariates. RESULTS: 180 patients were recruited (77% women, mean age 60.8). The prevalence of adherence was 59.1% (95% CI 48.1% to 71.8%). Patients on biologics showed higher adherence and perceived a higher medication need than the others; patients on second-line DMARDs had experienced more adverse events than the others. The variables explaining adherence in the final multivariate model were the type of treatment prescribed (second-line DMARDs OR=5.22, and biologics OR=3.76), agreement on treatment (OR=4.57), having received information on treatment adaptation (OR=1.42) and the physician perception of patient trust (OR=1.58). These effects were independent of disease activity. CONCLUSION: Treatment adherence in RA is far from complete. Psychological, communicational and logistic factors influence treatment adherence in RA to a greater extent than sociodemographic or clinical factors.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Balsa A, García de Yébenes MJ, Carmona L, et al. Multilevel factors predict medication adherence in rheumatoid arthritis: a 6-month cohort study. Ann Rheum Dis. 2021. PMID: 34844924. doi:10.1136/annrheumdis-2021-221163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。